Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anika/Staar Staarvisc II

This article was originally published in The Gray Sheet

Executive Summary

Sodium hyaluronate viscoelastic device gains FDA approval for use as an ophthalmic surgical aid via premarket approval application, announced April 27. The clear, viscous, injectable substance is used to protect delicate tissues inside the eye during ophthalmic surgeries like cataract removal and intraocular lens implantation. Staar Surgical has licensed the right to sell Staarvisc II from manufacturer Anika Therapeutics, and will offer it as part of a complete package for physicians to use for cataract procedures. Staar's original Staarvisc was approved by FDA in July 1999 (1"The Gray Sheet" July 12, 1999, p. 10)

You may also be interested in...



Staar Ramping Up Staarvisc Production Following FDA Approval

Staar Surgical's U.S. launch of Staarvisc viscoelastic solution will follow production ramp-up occurring over the next few months, the firm said following receipt of FDA approval July 7.

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.

UsernamePublicRestriction

Register

MT014793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel